Fielder Capital Group LLC Cuts Stock Position in Axon Enterprise, Inc $AXON

Fielder Capital Group LLC lessened its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 12.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,042 shares of the biotechnology company’s stock after selling 150 shares during the quarter. Fielder Capital Group LLC’s holdings in Axon Enterprise were worth $863,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after acquiring an additional 185,571 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Axon Enterprise by 15.9% in the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after acquiring an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after acquiring an additional 212,931 shares in the last quarter. Northern Trust Corp increased its holdings in Axon Enterprise by 1.2% in the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after acquiring an additional 8,794 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after acquiring an additional 611,418 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Up 2.7%

AXON stock opened at $735.95 on Friday. The company’s 50 day moving average price is $733.17 and its 200 day moving average price is $723.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a fifty-two week low of $422.38 and a fifty-two week high of $885.91. The firm has a market capitalization of $57.78 billion, a price-to-earnings ratio of 181.72, a PEG ratio of 27.82 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on AXON shares. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price for the company in a report on Tuesday, August 5th. Wolfe Research started coverage on shares of Axon Enterprise in a report on Monday, July 7th. They set an “outperform” rating for the company. JPMorgan Chase & Co. upped their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. Bank of America upped their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Finally, Raymond James Financial restated an “outperform” rating and set a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $841.64.

Insider Buying and Selling

In other news, President Joshua Isner sold 15,919 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president directly owned 238,379 shares in the company, valued at approximately $177,892,712.54. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the transaction, the chief financial officer owned 93,592 shares in the company, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,932 shares of company stock valued at $45,115,616 over the last three months. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.